CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
Aspirin +3 moredrug
Likely dose
Aspirin 81mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00771914
NCT00771914Phase 2Completed
CompareCT.gov

The Effects of Omega-3 Fatty Acids on Aspirin Resistance

University of Rochester·interventional·Posted Oct 15, 2008·Updated Nov 6, 2012

In Brief

A Phase 2 clinical trial evaluating Aspirin, Lovaza, and 2 other interventions for Increased Drug Resistance. Completed, enrolled 27 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if omega-3 fatty acids enhance the antiplatelet effects of aspirin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIncreased Drug Resistance
CountriesUnited States
CollaboratorsGlaxoSmithKline, American College of Clinical Pharmacy, Cornell University

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 15, 2008
Enrollment StartNov 1, 2008
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 17.7 years ago

Interventions

Aspirindrug

Aspirin 81mg tablet

Lovazadrug

Lovaza 4 grams

Both Aspirin and Lovazadrug

Lovaza 4 grams plus aspirin 81 mg

Placeboother

Capsule resembling fish oil and a tablet resembling aspirin